A Study of RO6799477 in Healthy Volunteers

A Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6799477 Following Oral Administration of Single Ascending Doses in Healthy Volunteers.

This single-center, randomized, double-blind, placebo-controlled, single dose study will investigate the safety, pharmacokinetics, pharmacodynamics of RO6799477 in healthy volunteers.

Inclusion Criteria:

• Male healthy volunteers, aged 18-45 years, inclusive
• Male volunteers with female partner of childbearing potential must agree to use an effective form of birth control during the study and for 3 months after discontinuation of treatment.
• Body Mass index (BMI) of 18-30 kg/m2, inclusive

Exclusion Criteria:

• Infection with human immunodeficiency virus antibody (HIV 1 and 2), Hepatitis B, hepatitis C
• Positive testing for drugs of abuse
• Any history of alcohol and/or drug of abuse addiction